OKYO to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients
OKYO Pharma Limited (OKYO.L) IND filing Q3 2022 and Phase 2 initiation Q4 2022
OKYO Pharma LTD (OKYO.L) Announces final audited results for the year ended 31 March 2021
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.
OKYO Pharma Limited (OKYO.L) Regulatory Development of OK-101 for Dry Eye Indications
London and Boston, MA, 29 June 2021 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory
OKYO Pharma Limited (OKYO.L) Publication of a Prospectus
Prospectus Publication Announcement
OKYO Pharma Limited (OKYO.L) Positive Data in an Animal Model using OK-201
OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
OKYO Pharma Limited (OKYO.L) Appointment of Chief Scientific Officer
OKYO announces the appointment of Dr Rajkumar Patil as Chief Scientific Officer
OKYO Pharma Limited (OKYO.L) Patent for treating Ocular Pain and Inflammation
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
OKYO PHARMA LIMITED (OKYO.L) Filing patent application for the use of Chemerin
OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS
OKYO PHARMA LIMITED (OKYO.L) Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board
OKYO , the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce
